SAM #12374114

Sole Source Procurement of Sysmex Automated Hematology Analyzer System for Naval Medical Center Portsmouth

Naval Medical Center Portsmouth is seeking a sole source contract for a Sysmex Automated Hematology Analyzer System to support advanced laboratory testing for high-acuity patient populations. - Government Buyer: - Department of Defense, Defense Health Agency (DHA), Naval Medical Center Portsmouth - DHA Contracting Activity (DHACA), Healthcare Contracting Division - Southeast - OEMs and Vendors: - Sysmex America, INC. (sole source manufacturer) - Products and Equipment Requested: - Sysmex XN-9100-202 Automated Hematology Analyzer System (1 unit) - Utilizes fluorescent flow cytometry for advanced cellular analysis - Unique technology for superior differentiation of white blood cell populations - Includes RU 20 reagent dilution unit for improved efficiency - BT-50 Terminal (1 unit) - Automation terminal for quality control and maintenance - CellaVision DI-60 Digital Morphology Analyzer (2 units) - Advanced RBC and body fluid software applications - CellaVision Remote Review Software Teams Edition (5 concurrent licenses) - Enables remote review of hematology slides - Turn Unit (TU) (1 unit) - Automated specimen sorting and archiving - TS-10 (1 unit) - Automated sample sorting system - Middleware Functionality - Comprehensive rule creation, auto/manual validation, integration with MHS Genesis LIS - Reagents, Controls, and Consumables - FDA-cleared, standardized, recurring shipments, sufficient for 190,000 CBC tests annually - Analyzer Accessories and Modules - QC modules, digital cell morphology, slide maker/stainer, specimen track, cell imaging, tube sorter, reagent management, UPS, printer - Services Requested: - Installation, validation, and implementation services - Ongoing maintenance and technical support - Unique or Notable Requirements: - System must meet FDA and OSHA standards - Designed for high-acuity oncology and immunocompromised patient populations - Cost-Per-Reportable-Result Agreement covering 190,000 CBC tests annually - Sole source justification based on unique Sysmex technology and clinical requirements - Estimated Contract Value: - Approximately $1,891,450.00 - Period of Performance: - Base year, four option years, and an optional six-month extension - Place of Performance: - Naval Medical Center Portsmouth, Portsmouth, VA

Description

The Government hereby submits a notice of intent to award a sole source Firm-Fixed-Price contract to Sysmex America, INC. for commercial-off-the-shelf (COTS) Cost-Per-Result-Reportable (CPRR) Automated Hematology Analyzer System. The contract will consist of a base year and four (4) option years, and one (1) Optional six (6) Month Option; the period of performance for the base year is 01July2026 - 30June2027. Sysmex America, INC.'s XN-9100-202 is the only source available that utilizes fluorescent flow cytometry, which analyzes RNA and DNA content and intracellular cellular structures rather than relying solely on impedance and light scatter. This technology provides superior differentiation of white blood cell populations and improves identification of immature and abnormal cells, including blasts, atypical lymphocytes, and immature granulocytes. These capabilities support higher flagging accuracy, reduced manual smear reviews, and earlier clinical decision-making, directly impacting patient care quality and safety. Another feature is the RU 20 reagent dilution unit that has reduced diluent changes, inventory and storage. The RU is unique to Sysmex and offered by no other vendor. These features not only reduce the manual workload on minimal undermanned laboratory staff and minimal storage area needed, but increases, accuracy, efficiency, and readiness for regulatory audits within space constraints due to delays in renovation for NMCP’s laboratory. The total estimated value is $1,891,450.00. Market research has determined that Sysmex America, INC. has a strategically sourced Federal Supply Schedule contract V797D-40235 for CPRR Automated Hematology Analyzer System which is valid through 31August2029. Responses to this notice must demonstrate clear and convincing evidence that competition would be advantageous to the Government, would not be cost or time prohibitive, and would not hinder the mission objective of Naval Medical Center Portsmouth. The determination not to compete this proposed contract action is solely within the discretion of the Government. Information received will normally be considered for the purposes of determining whether to conduct a competitive procurement. The Government will not be responsible for any costs incurred by responding to this notice. This is not a request for quote or proposals. Questions or comments to this Notice of Intent should be directed to Contract Specialist, Lisa Wilk at lisa.c.wilk.civ@health.mil and Contract Officer, Carol Uebelacker at carol.e.uebelacker.civ@health.mil. Please indicate in the subject of your email: Notice of Intent Question Submission 12374114.

View original listing